Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Nov 19, 2025 8:54 am EST

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 18, 2025 8:30 am EST

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 14, 2025 4:30 pm EST

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 12, 2025 8:30 am EST

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 10, 2025 8:30 am EST

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 03, 2025 8:30 am EST

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Oct 13, 2025 8:30 am EDT

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 09, 2025 8:30 am EDT

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 03, 2025 12:28 pm EDT

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 03, 2025 12:19 pm EDT

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023